Dr. Bosse on the Quality of Life With VEGF Plus Radium-223

Dominick Bosse, MD
Published: Tuesday, Oct 17, 2017



Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

There was a secondary endpoint that looked at quality of life, according to Bosse. There was no decrease in pain or improvement of quality of life. This is probably because the entry criteria allowed a maximum of patients with bone disease. The survival of these patients was very short, states Bosse.
 


Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

There was a secondary endpoint that looked at quality of life, according to Bosse. There was no decrease in pain or improvement of quality of life. This is probably because the entry criteria allowed a maximum of patients with bone disease. The survival of these patients was very short, states Bosse.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x